I rate Bio-Rad (BIO) with a buy rating. I start by mentioning that the low growth perspective is the negative aspect. For 2025, the company expects a 0.25% growth rate for its revenues, which might ...

The non-GAAP financial measures shown in the table above and discussed below exclude certain items detailed later in this press release under the heading “Use of Non-GAAP Reporting.” A reconciliation ...